LianBio to Participate in Upcoming Investor and Industry Events

Rhea-AI Summary

LianBio (Nasdaq: LIAN), a biotechnology company focused on innovative medicines for China and Asia, announced participation in several key conferences from November 14-18, 2022. Events include the BioCentury-BayHelix East-West Biopharma Summit, Goldman Sachs Asia Pacific Healthcare Forum, and Jefferies London Healthcare Conference. Notable sessions feature discussions on biotech and capital markets, alongside company presentations and 1:1 meetings. A live audio webcast will be available for the Jefferies conference via LianBio’s investor website.

SHANGHAI, China and PRINCETON, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that members of the management team will participate in the following upcoming investor and industry conferences:

• BioCentury-BayHelix East-West Biopharma Summit – November 14-18, 2022
  • Panel: BioCentury Scene Setter Report: Does East-West Matter? – November 15 at 9:00 am PT
  • Panel: Capital Session I: Capital Markets Showcase Workshop: A Mountain of Dry Powder – November 16, 2022 at 1:15 pm PT
  • Company Presentation – November 15, 2022 at 2:48 pm PT
  • 1:1 Meetings
• Goldman Sachs Asia Pacific Healthcare Forum – November 15-18, 2022
  • Panel: Biotech Reshaping – Revisit China and Global Strategy – November 15, 2022 at 9:00 am HKT
  • 1:1 Meetings
• Jefferies London Healthcare Conference – November 15-17, 2022
  • Fireside Chat – November 16, 2022 at 10:55 am GMT
  • 1:1 Meetings
    

A live audio webcast of the Jefferies London Healthcare Conference will be accessible from the Investors section of LianBio’s website at https://investors.lianbio.com/ with a replay available following the live event. To learn more about the BioCentry-BayHelix event, visit the event website at https://conferences.biocentury.com/east-west-summit.

About LianBio

LianBio is a cross-border biotechnology company on a mission to bring transformative medicines to patients in China and other Asian markets. Through partnerships with highly innovative biopharmaceutical companies around the world, LianBio is advancing a diversified portfolio of clinically validated product candidates with the potential to drive new standards of care across cardiovascular, oncology, ophthalmology, inflammatory disease and respiratory indications. LianBio is establishing an international infrastructure to position the company as a partner of choice with a platform to provide access to China and other Asian markets. For more information, please visit www.lianbio.com.

For investor inquiries, please contact:

Elizabeth Anderson, VP Communications and Investor Relations

E: elizabeth.anderson@lianbio.com

T: +1 646 655 8390

For media inquiries, please contact:

Josh Xu, Director of Communications

E: josh.xu@lianbio.com

T: +86 136 6140 8315

Katherine Smith, Evoke Canale

E: katherine.smith@evokegroup.com

T: +1 619 849 5378

FAQ

What conferences is LianBio participating in November 2022?

LianBio will participate in the BioCentury-BayHelix East-West Biopharma Summit, Goldman Sachs Asia Pacific Healthcare Forum, and Jefferies London Healthcare Conference from November 14-18, 2022.

When is LianBio's presentation at the BioCentury-BayHelix Summit?

LianBio's company presentation at the BioCentury-BayHelix Summit is scheduled for November 15, 2022, at 2:48 pm PT.

How can I access the Jefferies London Healthcare Conference webcast?

The live audio webcast of the Jefferies London Healthcare Conference can be accessed from the Investors section of LianBio's website, with a replay available afterwards.

What topics will be discussed at the Goldman Sachs Asia Pacific Healthcare Forum?

The Goldman Sachs Asia Pacific Healthcare Forum will include a panel discussion titled 'Biotech Reshaping – Revisit China and Global Strategy' on November 15, 2022.

What is LianBio's mission?

LianBio is dedicated to bringing transformative medicines to patients in China and other Asian markets through partnerships with global biopharmaceutical companies.